Category Archives: Uncategorized

Research – Antimicrobial resistance profile of Escherichia coli isolates recovered from diarrheic patients at Selam Health Center, Addis Ababa, Ethiopia

Academic Journals

Abstract

Antimicrobials have been playing an important role in preventing illness and death associated with infections due to bacteria. However, the emergence and spread of resistance by pathogens have decreased the effectiveness of the commonly prescribed antimicrobials. Intestinal Escherichia coli are among bacterial pathogens that are endowed with such resistance traits because they are important source and reservoir of genes that encode antimicrobial resistance. To determine the antimicrobial resistance profile of fecal isolates of E. coli from diarrheic patients. Stool samples were collected consecutively from 100 individuals who visited Selam Health Center during the study period, April to June 2018. Samples were collected and transported under sterile condition to the National Clinical Bacteriology and Mycology reference Laboratory, Ethiopian Public Health Institute. The samples were streaked on MacConkey agar and incubated overnight at 37°C. E. coli isolates were further confirmed using conventional biochemical tests. Antimicrobial susceptibility status was determined using the disk diffusion method on Mueller Hinton agar as recommended by the Clinical Laboratory Standard Institute. The raw data was compiled and entered to spreadsheet and analysis was done using SPSS Version 20 with p-value ≤0.05 considered statistically significant. Out of the 100 patients, 43 were female and the rest were male. Confirmed E. coli were isolated from 73 individuals. Antimicrobial susceptibility testing showed that E. coli isolated in this study were highly resistant to trimethoprim-sulfamethoxazole 49 (67.1%) and amoxicillin-clavulanic acid 47(64.4 %). No isolates showed resistance to gentamicin and tobramicin.  Of all the isolates, 11(15.1%) were multidrug resistant. No association was observed between antimicrobial resistance status and sex of individuals included in this study. However, there was an association between age and resistance patterns. Resistance to commonly prescribed antibiotics among E. coli isolated in this study was high and a considerable proportions of the strains were multidrug resistant. This is an indication for an alarming rate of resistance of intestinal E. coli to first line antimicrobials. To reduce the problem, regular monitoring and education for the community are very important.

Research – Feeding pets raw food is not considered by pet owners as a significant source of infections

Science Daily 260px-YellowLabradorLooking_new

An extensive international survey conducted at the University of Helsinki indicates that pet owners do not consider raw food to considerably increase infection risk in their household. In the survey, targeted at pet owners, raw food was reliably determined to be a contaminant only in three households.

The safety of feeding raw food to pets has become a topic of debate on a range of forums, but so far, no outbreaks of contamination among humans caused by raw pet food have been reported. Raw food denotes any meat, internal organs, bones and cartilage fed to pets uncooked.

Now, a survey conducted at the Faculty of Veterinary Medicine investigated perceptions on food-transmitted pathogens among pet owners who feed their pets raw food.

A total of 16,475 households from 81 countries responded to the survey. Out of these, only 39 households (0.24%) reported having been contaminated by pet food, and were also able to name the pathogen. The most common pathogens reported were Campylobacteria followed by Salmonella, in addition to which there were occurrences of Escherichia coli, Clostridium, Toxoplasma and a single Yersinia infection.

Research – H test for exclusion: A guide to an intervention approach to lessen the risk of aflatoxin‐contaminated foods in sorely contaminated regions

Wiley Online

Abstract

This research was done on the assumption that the risk for hepatocellular carcinoma (HCC) development that attributed to the consumption of highly contaminated food (HCF) with aflatoxin, may have a major contribution to the total of expected risk. If this hypothesis is true, it is easy to apply an effective and low‐cost intervention approach by excluding HCF and then subjecting it to treatments before use. To examine this hypothesized, H test for exclusion (Hx) model was developed as a computer program, in order to estimates the daily intake, the margin of exposure, and HCC cases per 105individuals for selected groups of contaminated food samples. To show how this model works, the model was demonstrated in a real example. The obtained results showed that the actual application of excluding HCF would result in a reduction of the expected cancer cases by 58%. Further, this model illustrates comparisons between permitted and nonpermitted samples with regards to international legislation. The model is particularly suitable for regions where contaminated crops and foods are prevalent. It is also convenient for addressing chronic exposure of commonly consumed food commodities to lower contamination levels.

Practical applications

For aflatoxin in contaminated crops, the Hx program can be used in order to estimates the daily intake, the margin of exposure (MOE), and the expected hepatocellular carcinoma (HCC) cases per 105. Furthermore, it provides a smooth rapprochement between non‐permitted and permitted samples in accordance with international legislation. In fact, the actual application of the model in regions where contaminated crops and foods are predominant can lead to efficient treatments with limited economic losses by excluding HCF.

Research – Novel Bacteriocin a Promising New Treatment for Resistant Listeria monocytogenes

Contagion Live

A novel bacteriocin appears promising as a new treatment option for antibiotic-resistant Listeria monocytogenes infection just as a multistate outbreak of the foodborne bacteria has claimed 2 lives in the United States.

With a fatality rate that can reach as high as 30%, L monocytogenes is considered a pressing public health threat that can have a serious impact on immunocompromised individuals and pregnant women, newborn children, and the elderly.

Because of its high mortality rate and increasing resistance to currently available antibiotics, treating L monocytogenes is becoming more and more challenging. But investigators with RMIT University in Melbourne, Australia, have discovered a promising new treatment in the form of a bacteriocin produced by Lactobacillus plantarum B21. The research team presented their findings at the American Society for Microbiology (ASM) and the European Society for Clinical Microbiology and Infectious Diseases (ESCMID) Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance.

Investigators played with multiple culture conditions to find a set that would foster high bacterial growth and/or high bacteriocin production. They also used gas chromatography mass spectrometry (GC‐MS)-based metabolomics to evaluate cellular and functional behavior of L plantarum B21. The structure of bacteriocin was analyzed using 2‐dimensional nuclear magnetic resonance spectroscopy (NMR). In order to assess the effectiveness of bacteriocin against a range of target strains of bacteria, the team relied on well diffusion assays and electron microscopy.

Research – Identification and genotyping of Listeria monocytogenes in the chicken shredding line

Wiley Online

Abstract

The present research was carried out to determine the presence of Listeria monocytogenes in the equipment, staff, and products in the chicken shredding facilities operating in Samsun, and to serotype and genotype the isolates by PCR and PFGE analysis, respectively. Of the total of 192 samples tested, 25 were found to be L. monocytogenes positive from which 51 isolates were acquired. In serotyping of the 51 isolates; 47 (92.2%) and four isolates (7.8%) were identified as 1/2a (3a) and 1/2c (3c), respectively. Twenty‐six of the 51 isolates (51%) were resistant to at least one antibiotic, and 13 (25.5%) were resistant to more than one antibiotic. In the PFGE evaluation, at least 80% similarity was taken as a basis, and in the dendrogram, it was determined as a result of restricting with the Apal enzyme that the isolates were distributed to 25 different clusters and 45 subsets, and as a result of restricting with the AscI enzyme, they were distributed to 29 different clusters and 36 subsets.

Practical Application

Listeria monocytogenes constitutes a major problem for the food industry due to its widespread availability in nature and its role as an environmental contaminant in food processing plants.

USA – Plastikon Healthcare Issues Voluntary Nationwide Recall of Milk of Magnesia Oral Suspension 2400 mg/30 mL due to Microbial Contamination

FDA

Summary

Company Announcement Date:
FDA Publish Date:
Product Type:
Drugs
Reason for Announcement:
Microbial Contamination
Company Name:
Plastikon Healthcare
Brand Name:
Major Pharmaceuticals
Product Description:
Milk of Magnesia Oral Suspension 2400 mg/30 ml

Company Announcement

Lawrence, KS, Plastikon Healthcare, LLC is voluntarily recalling Milk of Magnesia 2400 mg/30 mL Oral Suspension, lots 19027D and 19027E, to the patient level. Plastikon Healthcare initiated this recall because these product lots did not meet Plastikon’s in-house microbiological specification for Total Aerobic Microbial Count.

This product is packaged for institutional use and is sold to clinics and hospitals, the patient population most likely to use the product are likely immunocompromised. Patients with compromised immune systems, such as patients in hospitals and nursing homes, have a higher probability of developing potentially life-threatening infections after taking a contaminated product. To date, Plastikon has not received any customer complaints or reports of adverse events related to this issue. Milk of Magnesia 2400 mg/ 30 mL is indicated for the occasional relief of constipation (irregularity) in adults and children 12 years and older or for children under 12 as recommended by a doctor.

Milk of Magnesia 2400 mg/ 30 mL Oral Suspension is privately labeled by Major Pharmaceuticals® and packaged in cartons as indicated below. The affected lots were distributed to Major Pharmaceuticals Distribution Center (wholesaler), who may have shipped to clinics, hospitals and healthcare providers, in the United States, in August 2019.

Carton NDC Lot Number Expiration Date Strength Configuration/Count
0904-6846-73 19027D 2021 July 2400 mg/30 mL Carton containing 100 single dose cups (10 trays x 10 cups)
0904-6846-73 19027E 2021 July 2400 mg/30 mL Carton containing 100 single dose cups (10 trays x 10 cups)

Plastikon Healthcare places the utmost emphasis on patient safety and product quality at every step in the manufacturing and supply chain process. Plastikon Healthcare has notified its direct customers via a recall letter to arrange for return of any recalled product.

Anyone with an existing inventory of the lots, which are being recalled, should stop use and distribution and quarantine immediately. Inform healthcare professionals in your organization of this recall. For clinics, hospitals, or healthcare providers that have dispensed product to patients, please notify these patients regarding the recall. For additional assistance, call Plastikon Healthcare at 785-330-7100 (Monday through Friday, 8 a.m. to 5 p.m. CST).

For clinical inquiries, please contact Plastikon Healthcare using the below information.

Contact Center Contact Information Area of Support
Plastikon Healthcare 816-721-3269 (24 hours a day 7 days per week) To report adverse events or product complaints

Patients who are taking this product should consult with their healthcare provider or pharmacy to determine if they have the affected product lots. Patients with the affected lots should return the product to their pharmacy or contact Plastikon Healthcare (785-330-7100) for instructions on how to return their product and obtain reimbursement for their cost. Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA’s MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

  • Complete and submit the report Online
  • Regular Mail or Fax: Download form or call 1- 800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.

Milk of Magnesia label, top view

Research – Eugenol as an antimicrobial wash treatment reduces Campylobacter jejuni in postharvest poultry

Wiley Online

campy2

Image CDC

Abstract

The efficacy of the natural plant‐derived compound, eugenol (EG), as an antimicrobial wash treatment to reduce Campylobacter jejuni in postharvest poultry was investigated. The antimicrobial efficacy of EG was studied as a suspension, emulsion, or nanoemulsion treatment (two trials each). In each trial, chicken skin samples were inoculated with C. jejuni (∼7.2 Log CFU/sample), washed with treatments (0, 0.125, 0.25, 0.5, 1, or 2% EG corresponds to 0, 7.61, 15.22, 30.45, 60.90, or 121.8 mM, respectively) for 1 min, drip dried for 2 min, and then processed at 0, 8, and 24 hr of refrigerated storage (n = 5 samples/treatment/time point). All doses of the EG suspension consistently reduced C. jejuni counts with the greatest reduction (>2.0 Log CFU/sample) for the 2% dose when compared with controls (p < .05). EG emulsions or nanoemulsions did not provide any additional reduction in C. jejuni when compared to EG suspension. Our results suggest that EG could be an effective postharvest intervention strategy for reducing C. jejuni contamination on poultry products.

Practical Applications

Campylobacter jejuni, a leading cause of foodborne illness in humans, is strongly associated with the consumption of contaminated poultry products. Interventions reducing C. jejuni contamination in poultry would reduce the risk of subsequent human infections. In this study, the antimicrobial efficacy of eugenol was studied in three different delivery systems; suspension, emulsion, or nanoemulsion. Our results demonstrated that eugenol was effective in reducing C. jejuni counts on chicken skin and can be used as a potential strategy to reduce Campylobacter on poultry products.

USA – MDH Sambar Masala recalled for Salmonella risk

Food Safety News Screen Shot 2019-09-08 at 5.17.26 PM

House of Spices (India), packaging products under MDH brand names, is recalling various lots of “MDH SAMBAR MASALA” because of the risk of Salmonella contamination, according to a  recall notice posted on the FDA’s website.

The recalled product, produced by R-Pure Agro Specialities and distributed by House of Spices (India), were sold in retail grocery stores in Northern California.

USA – New Jersey Department of Health on Hepatitis A at Mendham Golf and Tennis Club

Food Poison Journal

The New Jersey Department of Health is working with the Mendham Township Health Department and the Mendham Golf and Tennis Club (MGTC) in response to a hepatitis A outbreak related to a food handler at the club. MGTC is a members only club.

Hepatitis A is an immediately reportable condition to the Department and the local health department; through this mechanism this case was identified.    The Department of Health is supporting the Mendham Township Health Department—which began immediately investigating. The food handler was excluded from work and a review of other food handlers for vaccination and proof of immunity was conducted.  Close contacts of the food handler were identified and given prophylaxis (vaccine or medication to prevent illness after exposure).

USA – Shigella Outbreak in Amador County

Outbreak News Today

Shigella - kswfoodworld

Image CDC

Amador County health officials announced this week that they are currently investigating a Shigella outbreak in their county. According to the announcement, there is a “significant increase in acute frequent diarrhea is being reported in Amador County.” The county, however, did not state how many illnesses are involved or the medical status of those who are sick. 
It is believed that the health department has determined the source but has been mum about naming it. The health department’s statement noted that: “Amador County Environmental Health and Public Health are completing an investigation and have enforced food safety practices at a lone establishment associated with reports of this illness.”